DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Wissenschaftliche Berater

Professor Dr. med. Christoph Wanner, Chairman

OA Med. Klinik u. Poliklinik I
Uniklinik Würzburg
Josef-Schneider-Str. 2
D-97080 Würzburg

Professor Dr. med. Markus Ketteler

CA Med. Klinik III
Klinikum Coburg GmbH
Ketschendorfer Str. 33
D-96450 Coburg

Professor Dr. med. Markus Hollenbeck

CA Klinik Innere Medizin II
Knappschafts KH Bottrop GmbH
Osterfelder Str. 157
D-46242 Bottrop

Dr. med. Torsten Meyer

Med. Klinik V
Klinikum Braunschweig
Salzdahlumer Str. 90
D-38126 Braunschweig